BostonPremier Wealth LLC Makes New Investment in Boston Scientific Co. (NYSE:BSX)

BostonPremier Wealth LLC acquired a new position in Boston Scientific Co. (NYSE:BSX - Free Report) during the fourth quarter, according to the company in its most recent filing with the SEC. The fund acquired 2,528 shares of the medical equipment provider's stock, valued at approximately $226,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Values First Advisors Inc. bought a new stake in shares of Boston Scientific in the 3rd quarter worth about $28,000. Dunhill Financial LLC increased its position in shares of Boston Scientific by 86.4% in the 3rd quarter. Dunhill Financial LLC now owns 328 shares of the medical equipment provider's stock worth $28,000 after purchasing an additional 152 shares during the last quarter. Global Wealth Strategies & Associates increased its position in shares of Boston Scientific by 423.7% in the 4th quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider's stock worth $28,000 after purchasing an additional 250 shares during the last quarter. West Oak Capital LLC bought a new stake in shares of Boston Scientific in the 4th quarter worth about $29,000. Finally, E Fund Management Hong Kong Co. Ltd. bought a new stake in shares of Boston Scientific in the 3rd quarter worth about $30,000. Institutional investors and hedge funds own 89.07% of the company's stock.

Boston Scientific Stock Up 0.9 %

BSX stock opened at $106.15 on Tuesday. Boston Scientific Co. has a 12 month low of $64.54 and a 12 month high of $107.17. The firm has a market cap of $156.44 billion, a PE ratio of 84.92, a P/E/G ratio of 2.79 and a beta of 0.80. The firm has a 50 day simple moving average of $94.88 and a 200 day simple moving average of $87.28. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.48 and a quick ratio of 1.02.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, beating the consensus estimate of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 18.11%. Equities research analysts forecast that Boston Scientific Co. will post 2.83 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

BSX has been the subject of several research analyst reports. Citigroup boosted their target price on shares of Boston Scientific from $107.00 to $122.00 and gave the stock a "buy" rating in a research report on Thursday, February 6th. Royal Bank of Canada boosted their price objective on shares of Boston Scientific from $105.00 to $116.00 and gave the company an "outperform" rating in a research report on Thursday, February 6th. BTIG Research boosted their price objective on shares of Boston Scientific from $84.00 to $93.00 and gave the company a "buy" rating in a research report on Monday, October 14th. StockNews.com raised shares of Boston Scientific from a "hold" rating to a "buy" rating in a research report on Wednesday, January 29th. Finally, Canaccord Genuity Group boosted their price objective on shares of Boston Scientific from $98.00 to $101.00 and gave the company a "buy" rating in a research report on Monday, December 9th. One equities research analyst has rated the stock with a hold rating, twenty-two have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Boston Scientific presently has a consensus rating of "Buy" and a consensus price target of $107.39.

Insider Activity at Boston Scientific

In related news, EVP Arthur C. Butcher sold 14,010 shares of the company's stock in a transaction on Monday, November 25th. The stock was sold at an average price of $89.27, for a total transaction of $1,250,672.70. Following the transaction, the executive vice president now directly owns 978 shares of the company's stock, valued at approximately $87,306.06. The trade was a 93.47 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP John Bradley Sorenson sold 6,528 shares of the stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $104.97, for a total value of $685,244.16. Following the completion of the sale, the executive vice president now directly owns 26,449 shares of the company's stock, valued at approximately $2,776,351.53. This represents a 19.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 53,830 shares of company stock valued at $5,149,969 over the last ninety days. Insiders own 0.50% of the company's stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.